Zydus's ₹11 billion Buyback is a Promoter Cash-out Dressed as Capital Discipline

Zydus Lifesciences has opened a ₹11 billion share buyback. The tender offer runs from June 4-10 and will buy back up to 8.73 million shares at ₹1,260 each, a 21% premium to the pre-revision price of about ₹1,039. The company raised the price from an initial ₹1,150 and cut the share count from 9.57 million, leaving the total spend unchanged.

Against net profit of ₹54.56 billion in 2025-26, the ₹11 billion spend is about a fifth of one year's earnings. It also dwarfs the 2025-26 cash dividend of ₹ 1 per share, around ₹1 billion, by roughly eleven to one.

At 0.87% of paid-up capital and about 1.04% of the ₹1.05 trillion market value, the small offer trims the share count from a little over 1 billion to 998 million. A reduction of less than 1% in the share base lifts earnings per share by too little to notice, which makes the stated aim of "improving return on equity" true on paper and meaningless in practice.

Strip of the language about returns, the offer does one thing well: it sends roughly three-quarters of the cash back to the founding Patel family. 

The promoter group owns about 74.96% and plans to tender its full entitlement. In a proportionate buyback, shareholders are paid in line with what they hold, so promoters take roughly ₹8.25 billion and the public gets the remaining ₹2.75 billion. The entitlement ratios help small shareholders a little: they have five shares accepted for every 49 held, an acceptance rate near 10.2%, against 0.75% for the general category. But that cannot offset who owns the company. In effect, the buyback is a tax-efficient way to return surplus cash to the founders.

This is a familiar move. Zydus has bought back shares roughly every two years: ₹7.5 billion at ₹650 in 2022, ₹6 billion at ₹1,005 in early 2024, and ₹11 billion now. The latest is the largest in rupee terms but only mid-sized as a share of equity; the 2022 buyback covered 1.13%. 

The repurchase price has nearly doubled in four years, tracking the stock's re-rating rather than any view that the shares are cheap. At ₹1,260, the offer is 5.4 times consolidated book value of ₹269.43 and 25.2 times consolidated earnings per share of ₹50.09, a little above the trading multiple. Anyone who tenders gets a fair premium, but no bargain.

The timing comes at a time of balance sheet stress. Zydus began 2025-26 with a  comfortable ₹78.08 billion in cash and investments. By the second July-September of 2025-2026 it had moved into net debt, even as it prepared to pay cash out. Net debt to equity was 0.16 times in end- March 2026, up from 0.04 times two years earlier. None of this, though, breaks management's stated limit of net debt being equal to EBITDA: the buyback uses barely 13% of 2025-26’s ₹84.75 billion EBITDA. The limit thus holds. It’s the direction of travel that is the worry.

The bigger issue is what else the money could do and the demands on cash. R&D took ₹22.73 billion in 2025-26, or 8.4% of revenue; capex. A MedTech build-out is underway; the deal pipeline is busy, with small bolt-on buys for the specialty business such as the proposed Amplitude Surgical orthopaedics deal in Europe, the earlier Nano Therapeutics cardiology purchase, and a search for a US asset to pair with its rare-disease launches. 

Every rupee tendered is a rupee that cannot go to any of these. The defence is that the targets are small bolt-on deals by design and that the balance sheet still has room, so the buyback does not get in the way. 

That defence holds for now, but it signals the future game. The buyback is legal, seemingly fair-priced, and in line with past practice. It is also a payout that mainly rewards insiders, does almost nothing for everyone else's per-share economics, and arrives just as the balance sheet has started to turn. For minority shareholders, the over 20% premium is the whole case. For the promoters, the immediate benefit is ₹8.25 billion.